Repatha in Singapore: When Statins Aren’t Enough for High Cholesterol (2026)

You’ve been taking a statin, watching your diet, exercising — and your LDL (“bad”) cholesterol still won’t come down enough. Or perhaps statins give you side effects you can’t tolerate. For people in this situation, a newer class of medication called a PCSK9 inhibitor — the best-known being Repatha (evolocumab) — can be a game-changer. Here’s a plain-English guide to what it is, how it works, and who it’s for, so you can have a more informed conversation with your doctor.

Why cholesterol matters

LDL cholesterol builds up in artery walls over years, driving atherosclerosis — the process behind most heart attacks and strokes. For people at high cardiovascular risk (those with existing heart disease, or with inherited very-high cholesterol known as familial hypercholesterolaemia), getting LDL low enough is one of the most important things they can do to protect themselves. Statins are the proven first step — but not everyone reaches their target on them, and some can’t tolerate them.

What is Repatha (a PCSK9 inhibitor)?

Repatha is the brand name for evolocumab, a PCSK9 inhibitor — a fully human monoclonal antibody. It has been available in Singapore since 2017. Normally, a protein called PCSK9 destroys the LDL receptors your liver uses to clear cholesterol from your blood. Repatha blocks PCSK9, so your liver keeps more of those receptors and removes more LDL. The result is a substantial drop in LDL — often around 60% — on top of what a statin already achieves.

How it’s taken

Unlike a daily tablet, Repatha is a self-administered injection under the skin (via a pre-filled pen), typically every two weeks or once monthly depending on the dose. Many people give it to themselves at home after being shown how, similar to other injectable medications.

What the evidence shows

Beyond lowering LDL numbers, the large FOURIER trial found that adding evolocumab to statin therapy reduced major cardiovascular events (such as heart attack and stroke) by around 15% over a couple of years in high-risk patients. In other words, it doesn’t just improve a lab result — it has been shown to reduce real cardiovascular events in the right patients.

Who is it for?

What about cost?

PCSK9 inhibitors are premium biologic medications and cost considerably more than generic statins. Pricing and any insurance or subsidy considerations vary, so the practical step is to discuss the current cost and your options directly with the clinic or your doctor. For many high-risk patients, the cardiovascular protection can justify it — but that’s a personalised decision that weighs your risk, your targets and the cost together.

Frequently asked questions

The bottom line

For people whose high cholesterol isn’t controlled by statins alone — or who can’t tolerate them — Repatha and other PCSK9 inhibitors offer a powerful, evidence-backed way to lower LDL and reduce cardiovascular risk. It’s not for everyone, and it doesn’t replace healthy habits, but for the right patient it can be genuinely important. If your numbers aren’t where they should be, ask your doctor whether it’s worth considering.

This article is for general information only and is not medical advice, a diagnosis, or a treatment recommendation. Cholesterol medication decisions must be made with a qualified doctor who knows your medical history. If you have concerns about your cholesterol or heart health, please consult a doctor.